Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines Inc (NQ: PRAX )

74.50 +1.44 (+1.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines Inc

< Previous 1 2 3 4 5 6 Next >
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine
Via Benzinga
What 6 Analyst Ratings Have To Say About Praxis Precision Medicine
Via Benzinga
Demystifying Praxis Precision Medicine: Insights From 7 Analyst Reviews
Via Benzinga
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction... 
Via Benzinga
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
Via Benzinga
PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Misses Revenue for Q2 2024
PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Are We Having Fun Yet? Stocks Sell Off On Massive Volume
In this video, I review the overall market, my game-plan with the indices, how our largest swings are holding up, and the stocks on my radar. 
Via Talk Markets
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Quarterly & Long-Term Portfolios For The Win
What a day for Meta! I was planning to add to my position, but the volume was too low. I would have been shaken out of most of it for the swing before it could become this position trade. 
Via Talk Markets
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
Needham rates Praxis Precision Medicines Buy with a $145 target. Key programs include ulixacaltamide for essential tremor (Phase 3 results expected in 2024) and PRAX-628 for focal seizures. 
Via Benzinga
Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
The companies are working on treatments for essential tremor, a tricky indication. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know
Via Benzinga
PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024
PRAX stock results show that Praxis Precision Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.